Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma markers for identifying patients with metastatic melanoma.
Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, Sznol M, Ariyan S, Molinaro A, Halaban R. Kluger HM, et al. Among authors: hoyt k. Clin Cancer Res. 2011 Apr 15;17(8):2417-25. doi: 10.1158/1078-0432.CCR-10-2402. Epub 2011 Apr 12. Clin Cancer Res. 2011. PMID: 21487066 Free PMC article.
MicroRNA signatures differentiate melanoma subtypes.
Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB. Chan E, et al. Among authors: hoyt k. Cell Cycle. 2011 Jun 1;10(11):1845-52. doi: 10.4161/cc.10.11.15777. Epub 2011 Jun 1. Cell Cycle. 2011. PMID: 21543894 Free PMC article.
A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma.
Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, Weidhaas JB, Slack FJ. Godshalk SE, et al. Among authors: hoyt k. Oncogene. 2011 Mar 31;30(13):1542-50. doi: 10.1038/onc.2010.536. Epub 2010 Nov 29. Oncogene. 2011. PMID: 21119596 Free PMC article.
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.
Armstrong AW, Lebwohl M, Warren RB, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp KA, Kisa RM, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo MJ, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Armstrong AW, et al. Among authors: hoyt k. JAMA Dermatol. 2024 Nov 27. doi: 10.1001/jamadermatol.2024.4688. Online ahead of print. JAMA Dermatol. 2024. PMID: 39602111
271 results